Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2017-07-19Clinical Trial Update: Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia [Phase 1, Phase 2]
Clinical trial update describing a Phase 1/Phase 2 study of CT-1530 in relapsed or refractory B-cell non-Hodgkin lymphoma, chronic lymphocyt…
-
CLINICAL_TRIALS research · 2017-07-17Clinical Trial Update: Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma [Phase 2, Phase 3]
A Phase 2/Phase 3 trial evaluating Cinobufacini tablets in combination with standard chemotherapy for diffuse large B-cell lymphoma; current…
-
CLINICAL_TRIALS trial_result · 2017-07-12Clinical Trial Update: Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy [Phase 3]
A Phase III trial evaluating RAD001 (everolimus) as adjuvant therapy in poor-risk diffuse large B-cell lymphoma after complete response to r…
-
CLINICAL_TRIALS research · 2017-07-07Clinical Trial Update: Assessment of the Minimal Residual Disease in DLBCL From Cell-free Circulating DNA by NGS [NA]
Completed clinical trial evaluating minimal residual disease in diffuse large B-cell lymphoma using cell-free circulating DNA detected by ne…
-
CLINICAL_TRIALS research · 2017-07-06Clinical Trial Update: Risk Adapted Therapy in Diffuse Large B Cell Lymphoma [Phase 2]
An update on a Phase 2 trial evaluating risk-adapted therapy for diffuse large B-cell lymphoma.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2017-06-23Clinical Trial Update: Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP) [Phase 2]
A Phase 2 trial evaluating whether gene expression markers can predict outcomes in patients with diffuse large B-cell lymphoma treated with …
-
FDA approval · 2017-06-22FDA Approved: RITUXAN HYCELA — Original Application (Genentech, Inc.)
FDA approved RITUXAN HYCELA (rituximab and hyaluronidase) under an Original Application by Genentech. The subcutaneous formulation provides …
-
CLINICAL_TRIALS trial_result · 2017-05-30Clinical Trial Update: Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer [Phase 2]
Phase 2 trial evaluating a conditioning regimen with alemtuzumab, fludarabine phosphate, and total-body irradiation followed by cyclosporine…
-
CLINICAL_TRIALS trial_result · 2017-05-30Clinical Trial Update: Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139) [Phase 2]
Phase 2 trial evaluating nivolumab in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after autologous stem cell transplant fai…
-
CLINICAL_TRIALS trial_result · 2017-05-25Clinical Trial Update: Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 trial evaluating a combination of vorinostat, rituximab, ifosfamide, carboplatin, and etoposide in adults with relapsed/refracto…
-
CLINICAL_TRIALS trial_result · 2017-05-25Clinical Trial Update: Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating bendamustine hydrochloride, rituximab, etoposide, and carboplatin in relapsed/refractory diffuse large B-cell lym…
-
CLINICAL_TRIALS trial_result · 2017-05-24Clinical Trial Update: Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 clinical trial evaluating a multi-modality approach combining Yttrium-90 ibritumomab tiuxetan, fludarabine, radiation therapy, and d…
-
CLINICAL_TRIALS withdrawal · 2017-05-23Clinical Trial Update: Safety and Efficacy Study of CNOP Chemotherapy in Diffuse Large B Cell Lymphoma [Phase 1]
A Phase 1 safety and efficacy trial of CNOP chemotherapy for diffuse large B-cell lymphoma has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2017-05-22Clinical Trial Update: Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma [Phase 2]
Phase 2 trial evaluating rituximab in patients undergoing donor peripheral blood stem cell transplantation for relapsed or refractory B-cell…
-
CLINICAL_TRIALS research · 2017-05-19Clinical Trial Update: Study of Biomarkers Using Tissue Samples From Older Patients With Diffuse Large B-Cell Lymphoma Treated With Combination Chemotherapy With or Without Rituximab on Clinical Trial ECOG-E4494
This update reports on a biomarker study using tissue samples from older patients with diffuse large B-cell lymphoma treated with combinatio…
-
CLINICAL_TRIALS withdrawal · 2017-05-19Clinical Trial Update: Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 2]
The Phase 2 trial of Brentuximab Vedotin, Bendamustine, and Rituximab for relapsed or refractory B-cell non-Hodgkin lymphoma has been withdr…
-
CLINICAL_TRIALS trial_result · 2017-05-17Clinical Trial Update: Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer [Phase 2]
Phase 2 trial evaluating haploidentical donor bone marrow transplantation in patients with high-risk hematologic cancers; results completed …
-
CLINICAL_TRIALS trial_result · 2017-05-17Clinical Trial Update: Biomarkers in Patients With Diffuse Large B-Cell Lymphoma Treated With Combination Chemotherapy With or Without Rituximab
Biomarker analyses from patients with diffuse large B-cell lymphoma treated with combination chemotherapy with or without rituximab are repo…
-
CLINICAL_TRIALS research · 2017-05-12Clinical Trial Update: R±CEOP90 Versus R±CEOP75 in Newly Diagnosed Young Patients With Medium/High-risk DLBCL [Phase 3]
Phase 3 trial update comparing R±CEOP90 versus R±CEOP75 in newly diagnosed young patients with medium/high-risk diffuse large B-cell lymphom…
-
CLINICAL_TRIALS trial_result · 2017-05-10Clinical Trial Update: Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma [Phase 2]
Phase 2 trial evaluating bortezomib plus vorinostat as maintenance after autologous stem cell transplant in non-Hodgkin lymphoma showed resu…
-
CLINICAL_TRIALS trial_result · 2017-05-08Clinical Trial Update: Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial of oral clofarabine in relapsed/refractory non-Hodgkin lymphoma completed with posted results.
-
CLINICAL_TRIALS research · 2017-05-02Clinical Trial Update: PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating PD-1 knockout EBV-specific cytotoxic T lymphocytes for advanced EBV-associated malignancies, includ…
-
CLINICAL_TRIALS trial_result · 2017-04-27Clinical Trial Update: Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell Lymphoma [Phase 1]
Phase 1 feasibility study evaluating the addition of bortezomib to the R-ICE chemotherapy regimen for relapsed or refractory diffuse large B…
-
CLINICAL_TRIALS trial_result · 2017-04-26Clinical Trial Update: Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma [Phase 2]
Phase 2 trial evaluating bendamustine plus rituximab in older patients with previously untreated diffuse large B-cell lymphoma has completed…
-
CLINICAL_TRIALS trial_result · 2017-04-24Clinical Trial Update: High-dose Intravenous Methotrexate Versus Intrathecal Methotrexate for Central Nervous System Prophylaxis in DLBCL [Phase 3]
A Phase 3 clinical trial compares high-dose intravenous methotrexate with intrathecal methotrexate for central nervous system prophylaxis in…